vs
PJT Partners Inc.（PJT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是PJT Partners Inc.的1.5倍（$772.1M vs $531.4M），Revvity净利率更高（12.7% vs 10.0%，领先2.7%），PJT Partners Inc.同比增速更快（12.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $138.6M），过去两年PJT Partners Inc.的营收复合增速更高（27.5% vs 9.0%）
PJT Partners Inc.是一家专注于顾问业务的全球投资银行，于2015年10月从黑石集团旗下拆分成立，独立运营原黑石的金融与战略咨询服务业务，为全球各类客户提供专业的投行顾问相关服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PJT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$531.4M
营收增速更快
PJT
高出7.1%
5.9%
净利率更高
RVTY
高出2.7%
10.0%
自由现金流更多
RVTY
多$23.2M
$138.6M
两年增速更快
PJT
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $531.4M | $772.1M |
| 净利润 | $53.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 23.1% | 14.5% |
| 净利率 | 10.0% | 12.7% |
| 营收同比 | 12.9% | 5.9% |
| 净利润同比 | 4.0% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PJTRVTY
| Q4 25 | $531.4M | $772.1M | ||
| Q3 25 | $442.3M | $698.9M | ||
| Q2 25 | $401.1M | $720.3M | ||
| Q1 25 | $321.9M | $664.8M | ||
| Q4 24 | $470.5M | $729.4M | ||
| Q3 24 | $320.3M | $684.0M | ||
| Q2 24 | $358.1M | $691.7M | ||
| Q1 24 | $327.1M | $649.9M |
净利润PJTRVTY
| Q4 25 | $53.4M | $98.4M | ||
| Q3 25 | $39.8M | $46.7M | ||
| Q2 25 | $32.9M | $53.9M | ||
| Q1 25 | $54.0M | $42.2M | ||
| Q4 24 | $51.3M | $94.6M | ||
| Q3 24 | $22.1M | $94.4M | ||
| Q2 24 | $28.3M | $55.4M | ||
| Q1 24 | $32.6M | $26.0M |
毛利率PJTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PJTRVTY
| Q4 25 | 23.1% | 14.5% | ||
| Q3 25 | 20.6% | 11.7% | ||
| Q2 25 | 19.1% | 12.6% | ||
| Q1 25 | 16.3% | 10.9% | ||
| Q4 24 | 21.9% | 16.3% | ||
| Q3 24 | 15.4% | 14.3% | ||
| Q2 24 | 18.0% | 12.4% | ||
| Q1 24 | 16.5% | 6.8% |
净利率PJTRVTY
| Q4 25 | 10.0% | 12.7% | ||
| Q3 25 | 9.0% | 6.7% | ||
| Q2 25 | 8.2% | 7.5% | ||
| Q1 25 | 16.8% | 6.4% | ||
| Q4 24 | 10.9% | 13.0% | ||
| Q3 24 | 6.9% | 13.8% | ||
| Q2 24 | 7.9% | 8.0% | ||
| Q1 24 | 10.0% | 4.0% |
每股收益（稀释后）PJTRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $538.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $308.2M | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PJTRVTY
| Q4 25 | $538.9M | $919.9M | ||
| Q3 25 | $400.5M | $931.4M | ||
| Q2 25 | $214.6M | $991.8M | ||
| Q1 25 | $194.3M | $1.1B | ||
| Q4 24 | $483.9M | $1.2B | ||
| Q3 24 | $148.8M | $1.2B | ||
| Q2 24 | $164.2M | $2.0B | ||
| Q1 24 | $215.5M | $1.7B |
股东权益PJTRVTY
| Q4 25 | $308.2M | $7.3B | ||
| Q3 25 | $228.6M | $7.4B | ||
| Q2 25 | $167.4M | $7.6B | ||
| Q1 25 | $148.8M | $7.6B | ||
| Q4 24 | $187.0M | $7.7B | ||
| Q3 24 | $159.1M | $7.9B | ||
| Q2 24 | $133.8M | $7.9B | ||
| Q1 24 | $174.6M | $7.8B |
总资产PJTRVTY
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.7B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.4B | $12.4B | ||
| Q4 24 | $1.6B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.4B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $155.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $138.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 26.1% | 21.0% |
| 资本支出强度资本支出/营收 | 3.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.92× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $480.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PJTRVTY
| Q4 25 | $155.7M | $182.0M | ||
| Q3 25 | $256.1M | $138.5M | ||
| Q2 25 | $190.4M | $134.3M | ||
| Q1 25 | $-75.9M | $128.2M | ||
| Q4 24 | $195.7M | $174.2M | ||
| Q3 24 | $180.5M | $147.9M | ||
| Q2 24 | $193.6M | $158.6M | ||
| Q1 24 | $-38.8M | $147.6M |
自由现金流PJTRVTY
| Q4 25 | $138.6M | $161.8M | ||
| Q3 25 | $240.9M | $120.0M | ||
| Q2 25 | $178.9M | $115.5M | ||
| Q1 25 | $-77.9M | $112.2M | ||
| Q4 24 | $195.3M | $149.8M | ||
| Q3 24 | $178.5M | $125.6M | ||
| Q2 24 | $193.0M | $136.6M | ||
| Q1 24 | $-39.2M | $129.7M |
自由现金流率PJTRVTY
| Q4 25 | 26.1% | 21.0% | ||
| Q3 25 | 54.5% | 17.2% | ||
| Q2 25 | 44.6% | 16.0% | ||
| Q1 25 | -24.2% | 16.9% | ||
| Q4 24 | 41.5% | 20.5% | ||
| Q3 24 | 55.7% | 18.4% | ||
| Q2 24 | 53.9% | 19.7% | ||
| Q1 24 | -12.0% | 20.0% |
资本支出强度PJTRVTY
| Q4 25 | 3.2% | 2.6% | ||
| Q3 25 | 3.4% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 0.6% | 2.4% | ||
| Q4 24 | 0.1% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.1% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率PJTRVTY
| Q4 25 | 2.92× | 1.85× | ||
| Q3 25 | 6.43× | 2.97× | ||
| Q2 25 | 5.79× | 2.49× | ||
| Q1 25 | -1.41× | 3.03× | ||
| Q4 24 | 3.81× | 1.84× | ||
| Q3 24 | 8.15× | 1.57× | ||
| Q2 24 | 6.84× | 2.87× | ||
| Q1 24 | -1.19× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PJT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
